These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9777131)

  • 21. Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase.
    Berrocal DH; Cohen MG; Spinetta AD; Ben MG; Rojas Matas CA; Gabay JM; Magni JM; Nogareda G; Oberti P; Von Schulz C; Doval H; Bazzino OO; Cagide A; Oliveri R; Grinfeld LR
    Am Heart J; 2003 Dec; 146(6):E22. PubMed ID: 14661011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of streptokinase neutralizing antibodies on fibrinolytic activity and reperfusion following streptokinase treatment in acute myocardial infarction.
    Nilsson JB; Nilsson TK; Jansson JH; Boman K; Söderberg S; Näslund U
    J Intern Med; 2002 Nov; 252(5):405-11. PubMed ID: 12528758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
    Topol EJ; Ohman EM; Armstrong PW; Wilcox R; Skene AM; Aylward P; Simes J; Dalby A; Betriu A; Bode C; White HD; Hochman JS; Emanuelson H; Vahanian A; Sapp S; Stebbins A; Moliterno DJ; Califf RM
    Circulation; 2000 Oct; 102(15):1761-5. PubMed ID: 11023929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction.
    El-Menyar AA; Altamimi OM; Gomaa MM; Dabdoob W; Abbas AA; Abdel Rahman MO; Bener A; Albinali HA
    Coron Artery Dis; 2006 Aug; 17(5):431-7. PubMed ID: 16845251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial.
    White HD; Barbash GI; Califf RM; Simes RJ; Granger CB; Weaver WD; Kleiman NS; Aylward PE; Gore JM; Vahanian A; Lee KL; Ross AM; Topol EJ
    Circulation; 1996 Oct; 94(8):1826-33. PubMed ID: 8873656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safe use of thrombolysis in the elderly.
    Wittry MD; Thornton TA; Chaitman BR
    Geriatrics; 1989 Nov; 44(11):28-30, 33-6. PubMed ID: 2509296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction.
    Kellett J; Clarke J
    Med Decis Making; 1995; 15(4):297-310. PubMed ID: 8544674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review.
    Dundar Y; Hill R; Dickson R; Walley T
    QJM; 2003 Feb; 96(2):103-13. PubMed ID: 12589008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
    Kent DM; Hayward RA; Griffith JL; Vijan S; Beshansky JR; Califf RM; Selker HP
    Am J Med; 2002 Aug; 113(2):104-11. PubMed ID: 12133748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombolytic treatment in acute myocardial infarction.
    Verstraete M
    Circulation; 1990 Sep; 82(3 Suppl):II96-109. PubMed ID: 2118432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stroke in patients treated with thrombolytic therapy for acute myocardial infarction. The thrombosis in myocardial infarction clinical trial and a review of placebo-controlled trials.
    Price TR
    Stroke; 1990 Nov; 21(11 Suppl):III8-9. PubMed ID: 2122557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction.
    Zahger D; Karagounis LA; Cercek B; Anderson JL; Sorensen S; Moreno F; Shah PK
    Am J Cardiol; 1995 Oct; 76(11):749-52. PubMed ID: 7572648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality of life six months after myocardial infarction treated with thrombolytic therapy. AUS-TASK Group. Australian arm of International tPA/SK Mortality Trial.
    Glasziou PP; Bromwich S; Simes RJ
    Med J Aust; 1994 Nov; 161(9):532-6. PubMed ID: 7968752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of reteplase with alteplase for acute myocardial infarction.
    Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators
    N Engl J Med; 1997 Oct; 337(16):1118-23. PubMed ID: 9340503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Coronary flow and hemorrhagic complications after alteplase and streptokinase administration in patients with acute myocardial infarction].
    Kostić T; Perisić Z; Milić D; Apostolović S; Martinović SS; Bozinović N; Mitov V; Vidanović M
    Vojnosanit Pregl; 2009 Mar; 66(3):218-22. PubMed ID: 19341228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
    Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML
    Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.
    Goodman SG; Langer A; Ross AM; Wildermann NM; Barbagelata A; Sgarbossa EB; Wagner GS; Granger CB; Califf RM; Topol EJ; Simoons ML; Armstrong PW
    Circulation; 1998 Feb; 97(5):444-50. PubMed ID: 9490238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
    Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
    J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.